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Effect of Multifactorial Treatment Targets and Relative Importance of
Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-
Cholesterol on Cardiovascular Diseases in Chinese Primary Care
Patients With Type 2 Diabetes Mellitus: A Population-Based
Retrospective Cohort Study
Eric Yuk Fai Wan, MSc; Colman Siu Cheung Fung, MBBS; Esther Yee Tak Yu, MBBS; Weng Yee Chin, MD; Daniel Yee Tak Fong, PhD;
Anca Ka Chun Chan, MStat; Cindy Lo Kuen Lam, MD
Background-—The relative effect of hemoglobin A1c, blood pressure, and low-density lipoprotein-cholesterol (LDL-C) (“ABC”
factors) on the prevention of cardiovascular diseases (CVD) among patients with type 2 diabetes mellitus is poorly understood. This
study aimed to evaluate the association of key clinical parameters on CVD risk using a multifactorial optimal control approach in
Chinese primary care patients with type 2 diabetes mellitus.
Methods and Results-—A population-based retrospective cohort study was conducted on 144 271 Chinese type 2 diabetes
mellitus primary care patients, aged 18 to 79 and without prior clinical diagnosis of CVD in 2008–2011. Cox regressions were
conducted to examine the association between the combinations of ABC targets (hemoglobin A1c <7%, blood pressure <130/
90 mm Hg, and LDL-C <2.6 mmol/L) and risks of CVD (overall), coronary heart disease, stroke, and heart failure. Achieving more
ABC targets incrementally reduced the incidence of total CVD and individual disease including coronary heart disease, stroke, and
heart failure, irrespective of other patient characteristics. Compared with suboptimal control in all ABC levels, achieving any 1, 2,
and all 3 ABC targets reduced the relative risk of CVD by 13% to 42%, 31% to 52%, and 55%, respectively. Among those achieving
only 1 ABC target, LDL-C reduction was associated with the greatest CVD risk reduction (42%), followed by blood pressure
reduction (18%), and hemoglobin A1c reduction (13%).
Conclusions-—To achieve the greatest risk reduction for the incidence of CVD, the ultimate goal of treatment should be to achieve
target control of hemoglobin A1c, blood pressure, and LDL-C. If it is not possible to achieve all 3 targets, efforts should be
prioritized on treating the LDL-C to minimize CVD risk. ( J Am Heart Assoc. 2017;6:e006400. DOI: 10.1161/JAHA.117.
006400.)
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D iabetes mellitus (DM) remains a growing global healthchallenge. There are currently 415 million patients with
DM worldwide, and this ﬁgure is predicted to increase to
642 million by 2040.1 Cardiovascular diseases (CVD) are the
dominant cause of mortality in diabetic populations, con-
tributing to 70% of deaths.2 The International Diabetes
Federation and the American Diabetes Association strongly
recommend maintaining optimal hemoglobin A1c (HbA1c),
blood pressure (BP), and low-density lipoprotein-cholesterol
(LDL-C) (“ABC”) levels for the primary prevention of CVD.3,4
Unfortunately, achieving target levels of all ABC risk factors
remains a signiﬁcant challenge as has been reported in
Canada, the United States, the United Kingdom, and
Europe.5–8 The beneﬁts of CVD risk reduction through better
control of all 3 factors is beyond doubt, but little is known
about the relative effects of controlling individual or various
combinations of these risk factors in diabetic populations.
To date, there have only been a few studies that have
explored the association between multifactorial risk factors
and CVD.9–12 These studies have typically examined the
number of factors controlled as none, any 1, any 2, or all 3
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risk factors, but the relative importance of these 3 risk factors
remains unclear. In clinical practice, physicians need to
understand the relative importance of treating individual
factors to help them prioritize the treatment goals in patients
who may not be able to tolerate treatment of all 3 conditions
synchronously such as those who may be at increased risk of
adverse effects, those with excessive polypharmacy, or to
help minimize treatment burden.13,14 Evidence on the relative
importance of treating each factor or combinations of factors
can help clinicians make the most informed decisions and can
also be used for shared decision making in diabetic patients
with multimorbidity. Previous studies included both type 1
diabetes mellitus (DM) and type 2 DM (T2DM) subjects, have
included patients recruited from hospital-based settings, have
had inadequate sample sizes to observe sufﬁcient end-point
events, or have been performed under very structured but
artiﬁcial settings such as randomized clinical trials.9–12 Given
the potential difference in pathophysiology of CVD in type 1
DM and T2DM,15 and difference in disease severity in
hospital-based patients and primary care patients, ﬁndings
from these previous studies may not be applicable to T2DM
patients managed in a real-world primary care outpatient
setting. This is important given recent trends to shift delivery
of diabetic care away from hospitals to primary care settings
in most developed countries.16 Also, most previous studies
have only considered baseline ABC measurements, ignoring
the changes that may occur during the follow-up period, and
have not shown the results of subgroup analyses describing
the association of multifactorial risk factors control on CVD in
different higher-risk subgroups such as smokers or those who
are obese, which is an area where more knowledge is needed.
This study aimed to address some of the gaps in the
existing literature by examining the association and relative
importance of achieving target control for individual and
combinations of ABC risk factors on CVD risk reduction
among Chinese primary care patients with T2DM and to
perform subgroup analyses to examine which patient charac-
teristics are associated with CVD risk.
Methods
Study Design
This was a retrospective cohort study. All subjects were
Chinese, aged from 18 to 79 years old, were clinically
diagnosed with T2DM as identiﬁed by the International
Classiﬁcation of Primary Care-2 (ICPC-2) code of “T90,”
without any CVD event before baseline, and were receiving
health services for DM in 1 of the 74 general outpatient clinics
of the Hong Kong Hospital Authority (HA). The HA is the
government organization coordinating all public-sector hospi-
tals and primary care clinics in Hong Kong. Clinical records
between August 1, 2008 and December 31, 2011 on all
subjects meeting the inclusion criteria were retrieved through
the HA’s administrative database. For each patient, the date
of the ﬁrst time having the ABC value recorded was deﬁned as
their baseline and they were followed up until the date of
occurrence of an outcome event, death, or last follow-up as of
the censoring date (November 30, 2015), whichever occurred
ﬁrst.
Consent of participants was not necessary as all data were
anonymous and were extracted through the computerized
administrative system of the HA. Ethics approval was received
from all the regional Institutional Review Boards of the Hong
Kong HA. The reported investigations have been carried out in
accordance with the principles of the Declaration of Helsinki
as revised in 2008.
CVD Identiﬁcation
Outcomes of interest included the following 4 events:
Clinical Perspective
What Is New?
• In Chinese primary care type 2 diabetes mellitus patients,
attainment of all 3 ABC targets (hemoglobin A1c <7%, blood
pressure <130/90 mm Hg, and low-density lipoprotein-C
<2.6 mmol/L) was achieved in only one tenth of patients.
• Achieving a greater number of ABC targets, irrespective of
the patient’s characteristics, incrementally reduced the risk
of total cardiovascular disease (CVD) and all its subtypes
including coronary heart disease, stroke, and heart failure.
• The relative importance of ABC control for the primary
prevention of CVD was found to be target low-density
lipoprotein-C, followed by target blood pressure, followed by
target hemoglobin A1c.
• Patients beneﬁtted the most from attaining all 3 ABC targets
compared with those with suboptimal levels in all 3 ABC in
the duration of diabetes mellitus <1 year group.
What Are the Clinical Implications?
• To achieve the greatest risk reduction for the incidence of
CVD, the ultimate goal of treatment should be to achieve
target control of hemoglobin A1c, blood pressure, and low-
density lipoprotein-C.
• If it is not possible to achieve all 3 targets, efforts should be
prioritized on treating the low-density lipoprotein-C to
minimize CVD risk.
• Our ﬁndings highlight the importance of optimal control of
multifactorial risk factors at an earlier disease stage, and
the need to promote and educate clinicians and patients of
the importance of target control of the modiﬁable risk
factors for the primary prevention of CVD.
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1. CVD event including coronary heart disease (CHD), stroke,
or heart failure;
2. CHD included ischemic heart disease, myocardial infarc-
tion, coronary death, and sudden death as identiﬁed using
ICPC-2 K74 to K76 or International Classiﬁcation of
Diseases, Ninth Edition, Clinical Modiﬁcation 410.x to
414.x, 798.x;
3. Stroke including fatal and nonfatal was identiﬁed using
ICPC-2 K89 to K91 or International Classiﬁcation of
Diseases, Ninth Edition, Clinical Modiﬁcation of 430.x to
438.x; and
4. Heart failure was identiﬁed using ICPC-2 K77 or Interna-
tional Classiﬁcation of Diseases, Ninth Edition, Clinical
Modiﬁcation 428.x.
Achieved ABC and Baseline Covariates
The achieved ABC value was deﬁned as the average of annual
ABC measurements from baseline to the date of last follow-up.
For instance, if the follow-up period was 4 years, then the
achieved mean value was calculated by averaging the baseline,
1-, 2-, 3-, and 4-year ABC values. Achieved values are
commonly used to evaluate the association between clinical
parameters and the incidence of morbidity.17–19 According to
local guidelines, the recommended target values for HbA1c, BP,
and LDL-C were <7%, <130/80 mm Hg, and <2.6 mmol/L,
respectively.20 All study subjects were stratiﬁed into 1 of the
following 8 groups according to whether achieved ABC values
achieved target or not (Group 1: none achieved the targets;
Group 2: only HbA1c achieved the targets; Group 3: only BP
achieved the targets; Group 4: only LDL-C achieved the targets;
Group 5: only HbA1c and BP achieved the targets; Group 6: only
HbA1c and LDL-C achieved the targets; Group 7: only BP and
LDL-C achieved the targets; Group 8: all achieved the targets).
For example, if a patient had achieved HbA1c of 8%, BP of 125/
75 mm Hg, and LDL-C of 2.5 mmol/L, then this patient was
stratiﬁed into Group 7.
The baseline covariates comprised the following:
1. Patient’s sociodemographics: sex, age, and smoking
status;
2. Laboratory results: lipid proﬁle (LDL-C and total choles-
terol to high-density lipoprotein-cholesterol ratio), triglyc-
eride, urine albumin-to-creatinine ratio, and estimated
glomerular ﬁltration rate.
3. Clinical characteristics: body mass index (BMI), Charlson’s
Index, treated hypertension deﬁned as ICPC-2 code of
“K86” or “K87,” self-reported duration of DM, and family
history of DM.
4. Treatment modalities: use of insulin, metformin, sulfony-
lurea, other oral antidiabetic drugs, angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker, b-blocker,
calcium channel blocker, diuretic, other antihypertensive
drugs, and statins.
All laboratory assays were performed in accredited labo-
ratories by the College of American Pathologists, the Hong
Kong Accreditation Service, or the National Association of
Testing Authorities, Australia.
Data Analysis
Multiple imputation was adopted to deal with missing data for
all baseline covariates other than ABC.21 This approach can
effectively reduce unnecessary biases,21,22 raise the power of
the analysis, and produce more reliable and applicable
models.23–25 In this study, each missing value was imputed
5 times by the chained equation method. The same analysis
was performed for each of the 5 imputed data sets, and the 5
sets of results were combined using Rubin’s rules.26
Descriptive statistics for the baseline covariates of each
group were displayed after multiple imputation. Univariable
linear (for continuous variables) or logistic (for binary
variables) regressions were used to test whether there was
any signiﬁcant difference in baseline covariates across the
groups. The incidence rate was estimated by an exact 95% CI
based on a Poisson distribution for each group.27 The
differences of the incidence of CVD across the 8 groups
were examined using multivariable Cox proportional hazards
regression models with the adjustment of all baseline
covariates as shown above. The proportional hazards assump-
tion was checked by examining plots of the scaled Schoenfeld
residuals against time for the covariates. All models in the
study satisﬁed the proportional hazards assumptions and
showed no presence of multicollinearity. To avoid the
association of speciﬁc standard target for ABC levels and
potential bias because of severe disease at baseline, 3
sensitivity analyses: (1) changing HbA1c and BP targets to
7.5% and 140/90 mm Hg, respectively; (2) changing HbA1c
and BP targets to 8% and 140/90 mm Hg, respectively; and
(3) excluding subjects with follow-up period less than 1 year
were also conducted. Subgroup analyses were performed
subsequently by stratifying sex, age groups (<65 years;
≥65 years), duration of DM (<1 year; ≥1 year), smoking
status (smokers; nonsmokers), and BMI groups (<23 kg/m2;
23–24.9 kg/m2; BMI ≥25 kg/m2).
All signiﬁcance tests were 2-tailed and those with P<0.05
were considered statistically signiﬁcant. Statistical analyses
were performed in STATA Version 13.0.
Results
In total, there were 162 589 subjects who were Chinese,
aged between 18 and 79 years old, clinically diagnosed with
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T2DM, with valid ABC measurement, and received their DM
care in primary care clinics of HA between August 1, 2008
and December 31, 2011. After excluding 18 318 subjects
with prior history of CVD history or without follow-up after
baseline, 144 271 T2DM patients were included in the main
analysis. Data completion rates for each baseline covariate
were >95%.
Table 1 shows the baseline characteristics for the overall
cohort and for each of the groups after multiple imputation. In
general, there were slightly more females (53%) than males
(47%), mean age was 61.6 years (SD: 10.0 years), and the
mean duration of DM was 6.2 years (SD: 6.3 years). In the
study cohort, 40%, 31%, and 9% achieved 1, 2, and all 3 ABC
targets, respectively; 47%, 37%, and 45% met the target levels
for HbA1c, BP, and LDL-C.
The number, unadjusted incidence rate, and hazard ratio
of various CVD events for each group are shown in Table 2.
The incidence rates of CVD ranged between 10.9 and 25.7
per 1000 person-years among all groups during a median
follow-up period of 63.5 to 68.5 months. In general, the
more ABC targets achieved, the lower the CVD risk.
Compared with Group 1 (no targets achieved), achieving
only 1 of the ABC targets (Groups 2–4), any 2 of the ABC
targets (Groups 5–7), and all 3 ABC targets (Group 8) were
associated with 13% to 42%, 31% to 52%, and 55% reduction
in the incidence of CVD, respectively. Among Groups 2 to 4,
achieving LDL-C target only (Group 4) was associated with
the largest reduction in CVD risk of 42% compared with
Group 1. The relative CVD risk reduction for achieving LDL-C
and BP targets (Group 7) decreased further by 52%
compared with Group 1. Similar results were obtained for
CHD, stroke, and heart failure. The sensitivity analyses were
conducted after changing the target for ABC levels and the
exclusion of subjects with a follow-up period of <1 year. The
results were almost identical to the main analysis and the
pattern was even more obvious for less stringent treatment
targets.
Similar analyses were conducted on the following 11
subgroups: (1) females, (2) males, (3) age <65 years, (4)
age ≥65 years, (5) duration of DM <1 year, (6) duration of
DM ≥1 year, (7) smokers, (8) nonsmokers, (9) BMI <23 kg/
m2, (10) BMI between 23 and 24.9 kg/m2 and (11) BMI
≥25 kg/m2 and the corresponding adjusted hazard ratios
for the incidence of each outcome event were plotted
against the 7 groups (using Group 1 as the reference
group) in Figure 1. A similar pattern was observed for
incidence of total CVD, CHD, heart failure, and stroke and
the deviation from the overall cohort was small for each of
the 11 subgroups. Among all subgroups, the largest relative
risk reduction in CVD was 69% when all 3 targets were
achieved compared with none in the group with duration of
DM <1 year.T
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Figure. Adjusted hazard ratios for incidence of cardiovascular diseases among (A) all participants, (B) female, (C) male (D), age <65 years
old, (E) age ≥65 years old, (F) duration of diabetes mellitus (DM) <1 year, (G) duration of DM ≥1 year, (H) smoker, (I) nonsmoker, (J) body
mass index (BMI) <23 kg/m2, (K) BMI 23 to 25 kg/m2, and (L) BMI ≥25 kg/m2 by multivariable Cox proportional hazards regressions.
Hazard ratios were adjusted by age, sex, smoking status, total cholesterol to high-density lipoprotein cholesterol ratio, triglyceride, BMI,
urine albumin-to-creatinine ratio, self-reported duration of DM, diagnosed hypertension, family history of DM, estimated glomerular ﬁltration
rate, Charlson Index and the use of insulin, metformin, sulfonylurea, other oral diabetic drugs, angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker, b-blocker, calcium channel blocker, diuretic, other antihypertensive drugs, and statin at baseline. Group 1 (no
target achieved) was used as reference group; Group 2: only HbA1c (hemoglobin A1c) target achieved; Group 3: only blood pressure (BP)
target achieved; Group 4: only low-density lipoprotein-cholesterol (LDL-C) target achieved; Group 5: only HbA1c and BP targets achieved;
Group 6: only HbA1c and LDL-C targets achieved; Group 7: only BP and LDL-C targets achieved; Group 8: all targets achieved.
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Discussion
This is the ﬁrst study to evaluate the relative association of
target control of individual and combinations of ABC risk
factors on the reduction of CVD among Chinese primary care
patients with T2DM. In our study population, attainment of all
3 ABC targets was achieved in only one tenth of patients.
Achieving a greater number of ABC targets, irrespective of the
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Figure. Continued.
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patient’s characteristics, incrementally reduced the risk of
total CVD and all its subtypes including CHD, stroke, and
heart failure. Achieving target control of LDL-C was associ-
ated with the most signiﬁcant reduction of CVD risk,
suggesting that the relative importance of attaining ABC
targets for the primary prevention of CVD should be LDL-C
ﬁrst, BP second, and HbA1c third. Among all subgroups,
patients beneﬁtted the most from attaining all 3 ABC targets
compared with those with suboptimal levels in all 3 ABC in the
group with duration of DM <1 year, suggesting that early
optimization of the ABC risk factor control in earlier disease
stage is important.
The key ﬁnding of this study was understanding that not all
ABC risk factors are of equal importance in the reduction of
CVD risk in diabetic patients. Among Chinese primary care
patients with T2DM, the relative importance of ABC control
for the primary prevention of CVD was found to be target lipid
levels, followed by target BP, followed by target HbA1c. As
earlier studies had only focused on the association of
achieving target control for individual risk factors or number
of risk factors, this study helps to ﬁll a gap in the literature by
providing information on the relative importance of achieving
individual ABC targets or combinations of targets. A study
comparing the effectiveness of lowering ABC levels by
combining ﬁndings from epidemiological data and meta-
analyses found that the numbers needed to treat for the
prevention of 1 CVD event over 5 years were 119 for 0.9%
reduction in HbA1c, 44 for 1 mmol/L reduction in LDL-C,
and 34 for 10 mm Hg reduction in systolic blood pressure or
5 mm Hg reduction in diastolic blood pressure, and
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concluded that addressing lipid and BP control had much
larger beneﬁts on the prevention of CVD than glycemic
control.28 In terms of the tolerability and safety of pharma-
cological treatments, glucose-lowering therapies, in particular
intensive glycemic control, can increase the risk of severe
hypoglycemia and severe adverse events resulting in hospi-
talization or signiﬁcant disability.29 In contrast, lowering of
blood pressure or lipid levels can be achieved with drugs that
have relatively less dangerous side effects.30–32 A recent
review highlighted that effective low-cost statin regimens
(generic atorvastatin 40 mg daily costs around USD 2.6 per
month) can reduce at least 2 mmol/L in patients with LDL-C
of 4 mmol/L or above, and lowering by 2 mmol/L reduces
CVD risks by 45%.30 Weighing the beneﬁts and risks of ABC
factors based on current evidence, it appears that targeting
lipid control should be prioritized if all 3 cannot be achieved.
Our ﬁndings were consistent with the results of the Steno-
2 randomized clinical trial, which also concluded the crucial
importance of multifactorial interventions for established risk
factors in DM management.12 Another recent study con-
ducted in the United States demonstrated that diabetic
patients achieving 1, 2, and all 3 ABC targets incrementally
reduced CVD risk by 36%, 52%, and 62%, respectively, with
similar associations observed in CHD risk.9 A large popula-
tion-based study also pointed out that 34.1%, 38.4%, 36.2%,
and 29.3% of new onset of CVD, CHD, stroke, and heart failure
events could be prevented with adequate control of risk
factors in American diabetic patients.10 Another simulation
study projected that 38.3% of CHD events were prevented by
controlling all risk factors by applying the United Kingdom
Prospective Diabetes Study Risk Engine.11 We found that
patients with newly diagnosed DM received the greatest
beneﬁt from attaining all 3 ABC targets compared with those
with suboptimal levels in all 3 ABC targets. Several previous
studies also found that treatments were more effective for
diabetic patients in an earlier disease stage, highlighting the
importance of early optimal risk factor control to delay or
reduce complications.33–35
Similar to other countries, it was observed that only a small
proportion of Chinese diabetic patients achieve all 3 ABC
targets. The local prevalence of 9% for 3-factor target control
is slightly lower than rates reported in other countries, where
41% (27% for age <40), 14.3%, 12.0%, 6.5% in the United
Kingdom, the United States, Canada, and 8 European
countries, respectively, achieved 3-factor control. Clinical
inertia has been postulated to be the main reason underlying
the low prevalence of multitarget control. Clinical inertia
refers to a failure or reluctance to initiate or intensify
therapies when clinically indicated.36,37 The causes for clinical
inertia can be complex and multifactorial involving both
clinician and patient barriers.36,37 At the clinician level,
barriers include time constraints for consultation, concern
about the potential risk of harm, and lack of information and
training needed to achieve therapeutic goals. At the patient
level, barriers include anxieties about side effects of treat-
ments, difﬁculties with adhering to treatment regimens, costs
of medications, and other factors that contribute to excessive
treatment burden. Regardless of the reason, while risk factor
control remains suboptimal there is an urgent need to
understand how to best manage patients in a real-world
setting where 3-factor control may be the goal but is often not
feasible.
There were several strengths to this study. First, a
comprehensive evaluation on the association between ABC
targets and CVD with subgroup analyses was able to be
performed because of the large population-based sample.
Second, repeated measurements of ABC increased the
reliability of the ﬁndings. Third, all data were extracted from
a computerized administrative database, which helps assure
data accuracy.
There were also several limitations. First, this was a
retrospective cohort study, which can only provide associa-
tions but not causation. However, an identical conclusion was
obtained in the sensitivity analysis, which minimized reverse
causation. A further randomized clinical trial would be
required to reappraise our results. Second, the clinical
diagnosis of CVD depended on the ICPC-2 and International
Classiﬁcation of Diseases, Ninth Edition, Clinical Modiﬁcation
coding from the database, which might be subject to
misclassiﬁcation bias. While there were no studies to audit
the accuracy and completeness of diagnostic coding in this
database, previous studies demonstrated a nearly excellent
data completeness for drug prescription (99.98%), and all
clinicians are needed to provide accurate coding for each
episode of care in routine clinical practice in the HA.38,39
Third, the speciﬁc optimal targets for ABC levels in this study
were selected based on the current local guidance for the
management of DM in effect at the time of the subject
included. Although some international guidelines changed the
BP target from 130/80 to 140/90 mm Hg recently, there is
currently no consensus among international guidelines on the
optimal targets. Similar results in the sensitivity analyses after
changing to less stringent treatment targets were also
obtained. Fourth, lifestyle factors such as diet and exercise
were not available in the current study, but most of key
factors such as laboratory and drug data could reﬂect the
lifestyle and disease severity. Last, the current cohort only
comprised Chinese patients with local target protocols. An
external validation should be warranted to validate our model
by using a Chinese population in other regions.
In T2DM primary care patients, regardless of other patient
characteristics, achieving more ABC targets incrementally
reduced the risk of CVD. These ﬁndings support current
recommendations that control of all 3 ABC factors to target
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should be the ultimate goal for treatment. However, if it is not
possible to achieve target control of all 3 parameters, efforts
could be prioritized to achieving target LDL-C levels. Among
all subgroups, patients with newly diagnosed DM received the
most beneﬁt from attaining target control of all 3 ABC factors.
These ﬁndings highlight the importance of optimal control of
multifactorial risk factors at an earlier disease stage, and the
need to promote and educate clinicians and patients about
the importance of target control of the modiﬁable risk factors
for the primary prevention of CVD.
Acknowledgments
The authors wish to acknowledge the contributions of the Risk
Assessment Management Program for Diabetes Mellitus (RAMP-DM)
program team at the Hospital Authority head ofﬁce, and the Chiefs of
Service and RAMP-DM program coordinators in each cluster, and the
Statistics and Workforce Planning Department at the Hong Kong
Hospital Authority.
Sources of Funding
This study was funded by the Health Services Research Fund,
Food and Health Bureau, HKSAR Commissioned Research on
Enhanced Primary Care Study (Ref. no. EPC-HKU-2). No
funding organization had any role in the design and conduct of
the study; collection, management, analysis, and interpreta-
tion of the data; or preparation of the manuscript.
Disclosures
None.
References
1. International Diabetes Federation. IDF Diabetes Atlas. 7 ed. Brussels, Belgium:
International Diabetes Federation; 2015.
2. Gilmer TP, O’Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, Solberg
LI. Predictors of health care costs in adults with diabetes. Diabetes Care.
2005;28:59–64.
3. International Diabetes Federation Guideline Development Group. Global
guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104:1.
4. American Diabetes Association. Standards of medical care in diabetes—2015.
Diabetes Care. 2015;38:S70–S76.
5. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW.
Achievement of goals in US diabetes care, 1999–2010. N Engl J Med.
2013;368:1613–1624.
6. Stone MA, Charpentier G, Doggen K, Kuss O, Lindblad U, Kellner C, Nolan J,
Pazderska A, Rutten G, Trento M. Quality of care of people with type 2
diabetes in eight European countries. Diabetes Care. 2013;36:2628–2638.
DC_121759.
7. Healthcare Quality Improvement Partnership. National diabetes audit (2013–
2014 & 2014–2015)—report 1 care processes and treatment targets.
2016.
8. Grenier J, Leiter LA, Langer A, Goldin L, Teoh H, Connelly KA, Cheng AY,
Tan MK, Fitchett D, McGuire DK. Glycemic control and cardiovascular
risk factor management in patients with diabetes with and without
coronary artery disease: insights from the diabetes mellitus status in
Canada (DM-SCAN) survey. Eur Heart J Qual Care Clin Outcomes. 2016;2:
qcw013.
9. Wong ND, Zhao Y, Patel R, Patao C, Malik S, Bertoni AG, Correa A, Folsom AR,
Kachroo S, Mukherjee J. Cardiovascular risk factor targets and cardiovascular
disease event risk in diabetes: a pooling project of the Atherosclerosis Risk in
Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart
Study. Diabetes Care. 2016;39:668–676.
10. Vazquez-Benitez G, Desai JR, Xu S, Goodrich GK, Schroeder EB, Nichols GA,
Segal J, Butler MG, Karter AJ, Steiner JF. Preventable major cardiovascular
events associated with uncontrolled glucose, blood pressure, and lipids and
active smoking in adults with diabetes with and without cardiovascular
disease: a contemporary analysis. Diabetes Care. 2015;38:905–912.
11. Wong ND, Patao C, Malik S, Iloeje U. Preventable coronary heart disease
events from control of cardiovascular risk factors in US adults with diabetes
(projections from utilizing the UKPDS risk engine). Am J Cardiol.
2014;113:1356–1361.
12. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial
intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:
580–591.
13. May CR, Eton DT, Boehmer K, Gallacher K, Hunt K, MacDonald S, Mair FS, May
CM, Montori VM, Richardson A, Rogers AE, Shippee N. Rethinking the patient:
using burden of treatment theory to understand the changing dynamics of
illness. BMC Health Serv Res. 2014;14:281.
14. Mair FS, May CR. Editorial. Thinking about the burden of treatment. BMJ.
2014;349:g6680.
15. De Ferranti SD, De Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge
SN, Marx N, McGuire DK, Orchard TJ. Type 1 diabetes mellitus and
cardiovascular disease a scientiﬁc statement from the American Heart
Association and American Diabetes Association. Circulation. 2014;130:1110–
1130.
16. Gelding SV. Improving cardiovascular risk in type 2 diabetes: time to get
personal. United Kingdom: Oxford University Press; 2016.
17. Zhao W, Katzmarzyk PT, Horswell R, Li W, Wang Y, Johnson J, Heymsﬁeld SB,
Cefalu WT, Ryan DH, Hu G. Blood pressure and heart failure risk among
diabetic patients. Int J Cardiol. 2014;176:125–132.
18. Wan EYF, Fung CSC, Wong CKH, Chin WY, Lam CLK. Association of
hemoglobin A1c levels with cardiovascular disease and mortality in Chinese
patients with diabetes. J Am Coll Cardiol. 2016;67:456–458.
19. Sundstr€om J, Sheikhi R, €Ostgren CJ, Svennblad B, Bodegard J, Nilsson PM,
Johansson G. Blood pressure levels and risk of cardiovascular events and
mortality in type-2 diabetes: cohort study of 34 009 primary care patients. J
Hypertens. 2013;31:1603–1610.
20. Food and Health Bureau HKSAR. Hong Kong reference framework for diabetes
care for adults in primary care settings. 2010.
21. Royston P. Multiple imputation of missing values. Stata J. 2004;4:227–241.
22. Clark TG, Altman DG. Developing a prognostic model in the presence of
missing data: an ovarian cancer case study. J Clin Epidemiol. 2003;56:
28–37.
23. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol
Methods. 2002;7:147.
24. Steyerberg EW, van Veen M. Imputation is beneﬁcial for handling missing data
in predictive models. J Clin Epidemiol. 2007;60:979.
25. Moons KG, Donders RA, Stijnen T, Harrell FE. Using the outcome for
imputation of missing predictor values was preferred. J Clin Epidemiol.
2006;59:1092–1101.
26. Rubin DB. Multiple Imputation for Nonresponse in Surveys. United States: John
Wiley & Sons; 2004.
27. Ulm K. Simple method to calculate the conﬁdence interval of a standardized
mortality ratio (SMR). Am J Epidemiol. 1990;131:373–375.
28. Yudkin J, Richter B, Gale E. Intensiﬁed glucose lowering in type 2 diabetes:
time for a reappraisal. Diabetologia. 2010;53:2079–2085.
29. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C,
Wetterslev J. Targeting intensive glycaemic control versus targeting conven-
tional glycaemic control for type 2 diabetes mellitus. Cochrane Libr. 2011;
DOI: 10.1136/bmj.e1771. Available at http://www.leicestershirediabetes.
org.uk/uploads/123/documents/BMJ%20Cp%20of%20Metformin%20and%20
insulin%20v%20insulin%20type2.pdf. Accessed August 9, 2017.
30. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal
R, Danesh J, Smith GD, DeMets D. Interpretation of the evidence for the
efﬁcacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
31. Association AD. 8. Cardiovascular disease and risk management. Diabetes
Care. 2015;38:S49–S57.
32. Law M, Wald N, Morris J, Jordan R. Value of low dose combination treatment
with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ.
2003;326:1427.
DOI: 10.1161/JAHA.117.006400 Journal of the American Heart Association 12
Multifactorial ABC Target in T2DM Wan et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on N
ovem
ber 13, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
33. Chan J, So W, Ko G, Tong P, Yang X, Ma R, Kong A, Wong R, Le Coguiec F,
Tamesis B. The Joint Asia Diabetes Evaluation (JADE) Program: a web-based
program to translate evidence to clinical practice in Type 2 diabetes. Diabet
Med. 2009;26:693–699.
34. Alberti KGM, Zimmet P, Shaw J. International Diabetes Federation: a
consensus on Type 2 diabetes prevention. Diabet Med. 2007;24:451–463.
35. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at
diagnosis of type 2 diabetes associated with improved outcomes? UK
prospective diabetes study 61. Diabetes Care. 2002;25:1410–1417.
36. Khunti S, Davies MJ, Khunti K. Clinical inertia in the management of type 2
diabetes mellitus: a focused literature review. Br J Diabetes. 2015;15:65–69.
37. Lin J, Zhou S, Wei W, Pan C, Lingohr-Smith M, Levin P. Does clinical inertia vary
by personalized A1c goal? A study of predictors and prevalence of clinical
inertia in a US managed-care setting. Endocr Pract. 2015;22:151–161.
38. Wong MC, Jiang JY, Tang J-L, Lam A, Fung H, Mercer SW. Health services
research in the public healthcare system in Hong Kong: an analysis of over 1
million antihypertensive prescriptions between 2004–2007 as an example of
the potential and pitfalls of using routinely collected electronic patient data.
BMC Health Serv Res. 2008;8:1.
39. Fung V, Cheung N, Szeto K, Ngai L, Lau M, Kong J. Hospital authority
clinical vocabulary table–the past, the present, and the future. 2004
International Federation of Health Records Organization Congress Proceed-
ings. 2004.
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
DOI: 10.1161/JAHA.117.006400 Journal of the American Heart Association 13
Multifactorial ABC Target in T2DM Wan et al
 by guest on N
ovem
ber 13, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Fong, Anca Ka Chun Chan and Cindy Lo Kuen Lam
Eric Yuk Fai Wan, Colman Siu Cheung Fung, Esther Yee Tak Yu, Weng Yee Chin, Daniel Yee Tak
Cohort Study
Based Retrospective−Primary Care Patients With Type 2 Diabetes Mellitus: A Population
 Cholesterol on Cardiovascular Diseases in Chinese−Density Lipoprotein−Pressure, and Low
Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.117.006400
2017;6:e006400; originally published August 17, 2017;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/6/8/e006400
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on N
ovem
ber 13, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
